ID   LNGK9
AC   CVCL_D575
SY   LNGK-9 PCa; LNGK-9; LnGK9
DR   BTO; BTO:0005217
DR   cancercelllines; CVCL_D575
DR   Wikidata; Q54902856
RX   PubMed=9365544;
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: Metastatic; Left supraclavicular lymph node; UBERON=UBERON_8480056.
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0395 ! LNCaP
SX   Male
AG   50Y
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 05-10-23; Version: 17
//
RX   PubMed=9365544; DOI=10.1002/(SICI)1097-0045(19971101)33:3<166::AID-PROS4>3.0.CO;2-H;
RA   Gschwend J.E., Fair W.R., Powell C.T.;
RT   "Evaluation of the tetracycline-repressible transactivator system for
RT   inducible gene expression in human prostate cancer cell lines.";
RL   Prostate 33:166-176(1997).
//